Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary
November 3, 2022
Earnings Call Speaker Segments
Holly Manning
executiveThanks, operator. Hello, everybody, and good morning. It's great to have you join us for Agios' conference call covering the third quarter of 2022. Slides accompanying today's discussion can be found in the Investors area of our site, agios.com. Joining me today with prepared remarks are our Chief Executive Officer, Brian Goff; our Chief Medical Officer and Head of Research and Development, Dr. Sarah Gheuens; our Chief Commercial Officer, Richa Poddar; and Cecilia Jones, our Chief Financial Officer. Prior to beginning, I want to note for all of you that certain statements made during this call will contain forward-looking statements. Due to a range of risks, uncertainties and other factors — including those described in our latest filings with the SEC and any subsequent filings we may submit to the SEC — actual events and results may differ materially from what any forward-looking statements express or imply. With that said, I'll hand things over to Brian.
Brian Goff
executiveThank you, Holly, and hello everyone on this call. It's an honor to be with all of you today for my first quarterly earnings discussion at Agios since stepping into the Chief Executive Officer position close to 3 months ago, having taken on the role during August. This company possesses a deep-rooted history of scientific distinction and successful clinical delivery, and it stands right at the threshold of expanding its capacity to transform how rare and genetically defined conditions are treated. Given the fresh introduction of PYRUKYND alongside a broad clinical and preclinical pipeline, what lies ahead for Agios and the individuals it serves is truly thrilling < > this organization from day one. After coming aboard in August, as I have examined the operations in depth and gotten to know so many members of our exceptional team, my confidence and enthusiasm regarding Agios's future have only increased, for a few key reasons. First, the caliber of our culture and dedication to patients exceeds even what I had gathered during my due diligence. The shared commitment to our mission of bettering lives is evident in every function throughout the company and forms part of the very foundation of the choices we make, the individuals we bring on board, and why we show up to work each day. Second, considering the scale of our company, the range and depth of work happening across every part of the business is truly impressive. 2022 has proven to be a year of strong execution, with 5 pivotal studies and 2 early-stage trials in progress, a commercial launch continuing in the U.S. alongside active filings in the EU and Great Britain, plus a preclinical pipeline moving forward and wide-ranging business development activities aimed at further expanding that pipeline. And last, while the PYRUKYND launch had always appealed to me given my background and enthusiasm for rare diseases, I have come to more fully value the distinctive pairing of a first-in-class, first-in-disease launch with a pipeline offering substantial near-term chances to broaden indications; beyond the significance of this launch being the very first treatment ever made available to patients living with PK deficiency, it also provides a base upon which we can develop commercial expertise as we get ready for possible future growth into comparable yet considerably bigger rare diseases such as thalassemia. Agios holds every element needed to improve the lives of patients facing rare and genetically defined diseases, and I feel privileged to guide this team in pursuing long-term growth and value collectively. Moving to the third quarter and our latest achievements as laid out on Slide 5; we completed a number of important objectives and pushed others forward as we approach year-end. First, I'm delighted to extend a welcome to Cecilia Jones at Agios on her inaugural quarterly call serving as our Chief Financial Officer. Cecilia, who came on board at the close of September, brings deep experience from her work with rare disease-focused organizations and a proven record of financial leadership, strategy formation, and nurturing talent. She has quickly demonstrated herself as a terrific thought partner for me and the rest of the leadership group. Additionally, we reinforced our Board of Directors by bringing in Dr. Rahul Ballal and Cynthia Smith. Rahul and Cynthia bring deep biopharma leadership experience, and their know-how is exactly what we need to get the most out of what we can achieve. On the R&D side, our clinical and medical groups have stayed extremely active: they locked in a favorable CHMP opinion for PYRUKYND in the EU, kicked off the AG-946 MDS Phase 2a trial, got data from our thalassemia and PK deficiency clinical programs published in leading medical journals, put together a costly data set slated for presentation at ASH in December, and kept pushing enrollment forward in our thalassemia and sickle cell disease studies — Sarah will go into greater depth on that. Turning to commercial, having logged only 2 complete quarters since PYRUKYND won approval earlier this year, we're still making meaningful headway and remain very much in the active learning period of the launch. This quarter we pinpointed a number of key takeaways that let us sharpen our tactical strategy further and adjust our promotional blend so we can reach HCPs more effectively, build disease awareness and a sense of urgency around treating patients, and smooth the path to starting PYRUKYND. Richard is going to walk through a few of those takeaways and tactics in a moment. Then last week, we finished monetizing the TIBSOVO royalty that came to us through the Servier deal, which gives us over $130 million in capital to put toward high-value opportunities for the business. Looking ahead to the remaining weeks of this year, our priorities — laid out on Slide 6 — are crystal clear: keep enrollment growing across our pivotal thalassemia and sickle cell disease trials, obtain approval for PYRUKYND in PK deficiency in the EU and Great Britain, and keep building commercial momentum for our U.S. launch. I want to express my gratitude to every single Agios employee for the incredible work done this quarter and for helping me learn and get up to speed over these first few months; with that, I'll hand things over to Sarah.
Sarah Gheuens
executiveThank you, Brian. For the research and development organization, 2022 has represented twelve months of meaningful achievement. We've kept leading the way in PK activation, expanding how far this mechanism might reach across numerous conditions where unmet needs remain substantial, all while pushing forward programs earlier in our pipeline. On Slide 9, you can see that our clinical strategy around PK activation centers on changing the trajectory of hemolytic and acquired anemia through boosting red blood cell energy, health, and longevity. Our goal in enhancing red blood cell health overall is to influence what happens downstream of hemolysis and, in the end, to make patients feel and function better. So far, across sickle cell disease, thalassemia, and PK deficiency — our three furthest-along therapeutic areas — we've shown striking consistency within the biggest clinical dataset anywhere for a PK activator, and we're the first company to accomplish that. Let's go to Slide 10. When the ASH Annual Meeting convenes in December in New Orleans, over 20 abstracts from Agios and our collaborators will have been accepted for presentation, which further emphasize both the clinical consistency seen across diseases and the shared features of the pathophysiology underlying these conditions. In particular, we're eager to share new data showing the long-term effects of treatment with PYRUKYND in PK deficiency and thalassemia, plus SAD and MAD data for AG-946, our novel PK activator — expect more details on our ASH abstracts once they post online today at 9:00 a.m. Eastern Time. Now to mitapivat, our furthest-along PK activator, commercially called PYRUKYND, which in February became the initial FDA-approved therapy for PK deficiency, and we're continuing work to broaden this medicine's usefulness for every patient who has PK deficiency. This summer, we started two randomized, placebo-controlled trials of PYRUKYND in pediatric PK deficiency patients from ages 1 up to 18, as shown on Slide 11. We'll be enrolling two different groups of pediatric patients: ACTIVATE-kids is for those who don't receive transfusions on a routine basis, and ACTIVATE-kidsT is for those who do get transfusions regularly. On top of that, throughout this year we've been working hard to advance our marketing authorization application with the EMA for PYRUKYND in adults who have PK deficiency, and we were pleased to receive a positive CHMP opinion back in September. In the past month, we submitted a marketing authorization application for Great Britain through the European Commission Decision Reliance Procedure. We expect a decision from regulators in both the EU and Great Britain before the year is over. If approval is granted, we're committed to making sure patients can get access through our global managed access program. For adults in the EU and Great Britain who qualify and have a confirmed PK deficiency diagnosis, PYRUKYND can be accessed through this program, and we will provide the medication free of charge regardless of the patient's insurance situation. PYRUKYND will not be made available under the Global Managed Access Program for indications that remain under study or that fall outside the label, including thalassemia, sickle cell disease, and pediatric PK deficiency. Now on thalassemia, shown on Slide 12, our team feels considerable excitement about the prospect of establishing PYRUKYND as the first oral therapy that can improve hemolytic anemia and ineffective erythropoiesis across the entire spectrum of beta and alpha thalassemia patients, irrespective of transfusion needs. The strong results from the core phase of our Phase 2 trial covering non-transfusion-dependent beta and alpha thalassemia, which you can see on Slide 13, came out in the journal Lancet during August, and at ASH we intend to present newer findings from the extension stage of that study. Since roughly 60% of people with thalassemia presently lack any treatment choices, pushing our pivotal program ahead at maximum speed ranks as a top priority for our team. To be specific, we are striving to get a substantial share of patients signed up across a pair of worldwide pivotal studies for PYRUKYND, namely ENERGIZE and ENERGIZE-T, both of which are laid out on Slide 14. Just to remind everyone, ENERGIZE is a study that randomizes participants and uses a placebo control, and it enrolls patients with alpha and beta thalassemia who aren't on a regular transfusion schedule; the main endpoint they're measuring is hemoglobin response. ENERGIZE-T is a study that randomly assigns participants and uses a placebo for comparison. It involves individuals with alpha and beta thalassemia who receive regular transfusions. Regular transfusion here means they got between six and twenty units of red blood cells during the twenty-four weeks prior to being randomized. The main goal being measured is how well transfusions are reduced. On the sickle cell disease side, we're looking at PYRUKYND in a trial designed as an operationally seamless Phase 2/3 study named RISE UP. Our hope is that this becomes the first oral treatment possibility that can improve anemia, bring down VOCs, and lift quality of life by increasing the patient's own hemoglobin, resulting in reduced pain and tiredness. Moving to Slide 16, the Phase 2 segment is currently in the midst of patient enrollment. A total of 69 individuals will be assigned randomly, using a 1:1:1 allocation, to one of three arms: PYRUKYND at 50 milligrams administered twice a day, PYRUKYND at 100 milligrams administered twice a day, or a placebo that is matched. The primary endpoints consist of safety along with hemoglobin response, the latter being characterized by a rise of at least 1 gram per deciliter in the average hemoglobin concentration when comparing week 10 through week 12 against baseline. Our objective is to complete enrollment for the Phase 2 portion prior to the conclusion of this year. After the double-blind portion of Phase 2 concludes, we will review the data in its entirety before kicking off Phase 3. What we get from the primary endpoint is really just the starting point. From there, we'll bring in the secondary endpoints from the trial — things like changes in hemolysis markers, how often sickle cell pain crises occur, and fatigue as reported by patients. At the NIH and University of Utrecht, our partners are still giving PYRUKYND to sickle cell patients through extension studies, and those will give us longer-term treatment information that we can use when making our decision. If Phase 2 works out, that information will also allow us to lock in the dosing approach for the Phase 3 portion, exactly as the protocol lays out in advance. Because this study was designed to run seamlessly—meaning the very same clinical trial locations can be used to enroll two separate groups of patients, one in the Phase 2 and one in the Phase 3—we are able to move more quickly when going from 1 phase to the next. On top of that, depending on what Phase 2 shows, we can evaluate whether changes to the Phase 3 are needed, and doing so won't affect the statistical and regulatory elements of the trial. Next year, we will report the Phase 2 portion's results along with our go/no go decision. Turning to Slide 17, let's discuss AG-946, our innovative PK activator, which offers an opportunity to broaden our PK activator franchise even more and pursue a number of potential therapeutic avenues. In healthy volunteers, we've completed the Phase 1 single ascending dose and multiple ascending dose cohorts, and we'll present initial data at the ASH meeting in December that back up AG-946's profile as a strong PK activator. To collect information on this molecule in hemolytic anemia, we recently launched a sickle cell disease portion of the trial. Our clinical program for AG-946 in lower-risk MDS kicked off in September. Slide 18 lays out how MDS represents a varied collection of uncommon blood cancers. It's characterized by ineffective erythropoiesis, irregular cell maturation, dysplasia, and worsening cytopenias. Anemia shows up in roughly 90% of patients and stands as the most typical trait among those with lower-risk MDS, with around half eventually needing red blood cell transfusions. When it comes to anemia in lower-risk MDS, the main treatment options are few — erythropoiesis-stimulating agents or transfusions. Extra therapies are only indicated for certain MDS subtypes, and those tend to produce limited responses. We think AG-946 might boost how well red blood cells work and last by ramping up glycolysis and ATP generation, plus better differentiation of erythroid cells within bone marrow — which could ease anemia tied to ineffective erythropoiesis in lower risk MDS, much like what's seen in thalassemia. As for our clinical program, the opening move is the Phase 2a portion of the Phase 2a/2b trial you can see on Slide 19 — an open-label proof-of-concept effort testing a single dose level of AG-946 among patients who have lower-risk MDS; all told, we're quite happy with how far we've come on our 2022 key milestones during this quarter across each program, and we keep pushing forward on what's left among our priorities for the year. Having said that, I'll hand things over to Richa now.
Richa Poddar
executiveAppreciate it, Sarah. Like Brian pointed out, we spent this quarter learning continuously, evaluating strategy in depth, and sharpening both our priorities and our tactics so we can succeed during these first days after launch. The way we see it, success means building a meaningful commercial groundwork for the franchise around our PK activator. That groundwork matters a great deal to winning over the long haul, as you can see on Slide 21. Since PYRUKYND gives us our first actual real-world data point, we are building a solid real-world evidence base while also discovering what opportunities exist for the market's first PK activator, on top of being the very first therapy ever made available to patients who have PK deficiency. Though this opening launch will bring in only modest revenue, it puts in place our commercial capabilities platform for rare and genetically defined diseases and acts as a significant introduction for us into the wider hematology community, yet there is considerable overlap with possible future indications. Such learnings, capabilities, and relationships are going to prove invaluable while we get ready for several possible launches over the coming 4 to 5 years. During the third quarter, our second complete quarter of launching PYRUKYND, net U.S. sales came to $3.5 million, a figure reflecting greater patient demand that was partly offset by a modest inventory build during earlier launch quarters. In looking at this quarter's results, I want to begin with the main metrics we have tracked thus far, which appear on Slide 22. By September 30, we had reached a cumulative 84 unique patients whose PYRUKYND prescription enrollment forms were completed, which is a 64% rise relative to total PES at the close of Q2. Among those PES, a net of 56 patients were receiving PYRUKYND therapy, counting both newly prescribed patients and those staying on treatment, amounting to a 51% gain from quarter two. Converting a PES into a third prescription still takes roughly 4 to 6 weeks, and that pattern probably won't get shorter anytime soon. Discontinuations so far have stayed low. That said, during the fourth quarter, a large number of early patients will hit the 6-month mark for the efficacy assessment our label recommends. Once we see non-responding patients leave therapy, we can better judge adherence and persistence among those who remain on it. Just as we saw the previous quarter, these patients are arriving via a broad and unique prescriber base made up of 80 physicians spread throughout the country. The patients starting therapy span a variety of demographics and disease characteristics that match the adult PK deficiency population; on the payer side, our national account directors keep having constructive conversations with payers. The payer mix so far is consistent with what we expected before launch, which Slide 23 lays out. Payer policy is now being shaped to match the indication statement or the clinical trial eligibility criteria, exactly as we anticipated. Beyond that, the rules for prior authorization tied to uncommon specialty drugs usually require genetic testing, a specialist visit, and initial hemoglobin plus transfusion records. Now on Slide 24, we're happy about the ongoing enthusiasm for our Anemia ID kits, a no-cost genetic testing initiative created to assist patients given a broad diagnosis of hemolytic anemia of unknown etiology in obtaining a correct diagnosis. By September 30, over 5,300 kits had been requested, which is 26% higher than Q2, matching what we saw the prior quarter. Roughly 25% of kits have been finished, and among those completed tests the PK deficiency positivity rate is still in the mid-single-digit percentages. Following a positive test, about 60% were adults while 40% were pediatrics. When we consider how the launch is going so far, certain key elements have matched our expectations, while others are generating lessons and tactical changes to sustain growth. PK deficiency is an ultra-rare disease lacking centers of excellence, meaning most physicians see only a small number of patients who have diagnosed or suspected PK deficiency. Because of that, this disease is not well understood and frequently falls through the cracks during diagnostic triage, as Slide 25 shows. Even with PYRUKYND approved, that hasn't produced a swift shift toward diagnosing and treating at the pace we expected. Part of the reason is that we're pushing back against entrenched behavior, so ongoing education about — regarding how essential differential diagnosis via genetic testing is remains critically important. We're also seeing that past the physician, empowering and activating patients to advocate for themselves regarding diagnosis and treatment is just as important, perhaps even more so and more effective. Turning to the fourth quarter, our focus has been on assessing tactical changes and localized experiments to scale up initiatives that deliver results and address holes in our loan strategy informed by these fresh lessons. Crucially, the difference PYRUKYND makes in patients' lives is clear, and we're heartened by these early launch wins and the positive experiences we're building with the wider PK deficiency community. Still, there's far more work remaining for us to do for these patients. As I mentioned at the start, these lessons, our accumulated knowledge and the relationships we're forming are positioning us for success as we keep broadening PYRUKYND's applicability to every eligible patient with PK deficiency, and over the longer term for other genetically defined diseases. With that, I'll hand things over to Cecilia for the third quarter financial review.
Cecilia Jones
executiveThanks, Richa. You can find our Q3 2022 financial results in this morning's press release, and I'll give you a summary of those. Our 10-Q filing later today will provide more detail. If we look at Slide 27, as Richa mentioned, PYRUKYND net revenue came to $3.5 million in the second quarter. On a weeks-on-hand basis, PYRUKYND inventory stayed a bit below where we finished Q2 for the entire quarter. Keep in mind that we expect inventory to stay at low levels because our distribution network is limited to a single specialty pharmacy and a single specialty distributor. Gross to net remains within the 10% to 20% range, consistent with expectations for additional rare disease launches. The quarter's cost of sales was $517,000. Moving to operating expense, R&D came in at $65 million for Q3, which is $1 million higher than Q3 of 2021. SG&A expenses totaled $29.1 million in Q3, an increase of $1.9 million versus Q3 2021. This rise in SG&A was mostly driven by higher workforce-related expenses. TIBSOVO royalty revenue, recorded under royalty income from gain on sale of oncology business on our income statement, was $4.4 million. Because these royalty rights were sold to Sagard Healthcare Partners, TIBSOVO royalty income will come to an end in 2022. We closed the quarter with roughly $1 billion in cash, cash equivalents and marketable securities, and that figure does not include the $131.8 million in cash we received from Sagard for the sale of our TIBSOVO royalty rights. Given this cash position, we believe we can fund our current operating plan through major catalysts and reach cash flow positivity without raising additional equity; in today's environment, we recognize the value of a strong balance sheet, yet we're also careful to preserve this advantage and secure the capital needed to advance a promising clinical program and keep flexibility for BD. Our capital allocation remains sharply focused on only our top priorities, we're actively managing our expense base, and we're assessing ways to expand our pipeline. I'll hand the call back to Brian now to wrap things up.
Brian Goff
executiveAppreciate that, Cecilia. So, to wrap things up: we feel good about the ongoing momentum we're seeing throughout the company, and for Q4 our objectives are well defined. Our attention is on generating demand for the PK deficiency launch, and as we go we're taking what we learn to make our commercial capabilities platform stronger for growth down the road. Over in R&D, the team is committed to getting patients enrolled in our pivotal thalassemia and sickle cell disease trials, and at the same time we'll keep moving our pediatric PK efficacy work and our MDS studies forward. We also intend to act as careful stewards of the balance sheet and to keep assessing significant chances to create value. As we always do, we thank you for standing behind Agios; operator, at this point please open up the line so we can take questions.
Analyst
analystHello, Jason here, filling in for Greg. Nice work on the quarter. We appreciate you fielding our question. To begin with PYRUKYND, could you just assist us in understanding the way prescription enrollment forms turn into patients who are on PYRUKYND, and what factors encourage or discourage that conversion? Then perhaps a second one for Cecilia: given that two full quarters have passed since PYRUKYND's launch, what is your approach to forecasting and possibly giving revenue guidance? Thanks.
Brian Goff
executiveGreat. Thanks for the question. Maybe we will have Richa start with the first one.
Richa Poddar
executiveAlright, I appreciate the follow-up. When it comes to converting PES patients over to the pill, the PYRUKYND enrollment form — that prescription enrollment form — is what signs someone up for our patient support services. That's the path it takes. They're brought into myAgios, connected with a patient support manager, and that person guides them through the benefits investigation and helps them get access to therapy. From there, we work through the prior authorization criteria the payers have put in place, helping them understand what's required so they can get onto the pill. So when we gave the 84 and the 56, that 56 represents patients who've gotten at least one pill. Going from PES to pill takes roughly 4 to 6 weeks, and it's really driven by the PA criteria that the payers have established. I'll hand it over to Cecilia for the second part.
Cecilia Jones
executiveYeah. Thanks, Richa. I'd say we're still fairly early on with this launch, and there's plenty we're picking up, though we are thinking about the right moment to give guidance, and once it makes sense, we'll do so.
Ying Lon
analystGreat. Thank you.
Brian Goff
executiveThank you.
Marc Frahm
analystHello, and thank you for fielding my questions. Richa, I understand that we're fairly early on in this process, but could you describe what the usual reauthorization requirements are that you anticipate being used? Also, I suppose, in your view, how much wider might those be on average compared with the trial's primary end point?
Richa Poddar
executiveYes, Marc, I appreciate the question. The way to think about this is, once again, as you put it, it's somewhat early to speak to the details, since we are still figuring that out. And as you're aware, the majority of patients will reach that 6-month response evaluation time point during Q4. So we'll have a better understanding of what the reauthorization requirements will be. What we aim to do is genuinely assist payers in recognizing and grasping how our label has been structured. So that's our objective with them, meaning don't focus solely on hemoglobin or transfusion burden, but additionally consider chronic hemolytic parameters that shape how patients feel and function. So that forms part of the conversation taking place at present, so it remains too early to speak to details regarding that.
Brian Goff
executiveAlso, Marc, I want to mention that up to this point, we haven’t run into any meaningful obstacles at all when it comes to payers. We’re still at an early stage of the launch, but our expectation is that this won’t become a managed category, since it falls on the ultra-rare end; and I have to say the team is also achieving genuinely strong momentum with the payers.
Marc Frahm
analystAll right, that's useful. Then perhaps regarding the individuals being brought on during the most recent quarter, or even more lately — could you describe those newer additions in terms of whether it is, when it comes to success, roughly what you mentioned during the prepared remarks, Richa: bringing in those people who perhaps were receiving active care yet had received a diagnosis earlier, and now entering treatment? Or is the bigger factor something like Anemia ID and similar tools genuinely producing the fresh differential diagnosis?
Richa Poddar
executiveWell, I — pinning down those particulars, Marc, would prove somewhat difficult, since as we said earlier, Anemia ID was created to screen for hemolytic anemia with an unknown etiology; thus it isn't tailored to PKD. Consequently, there's no way for us to draw a straight line to determine which individuals came to light by way of Anemia ID. What we've aimed at and concentrated on is advancing education from the side of physicians, helping them recognize the necessity and the urgency of identifying PKD and elevating it within the diagnostic triage workflow, which at present moves more slowly there, correct? So that illness-related education from a physician perspective must carry on and stays a priority for us. And < > looking at the opposite side, we likewise wish to ensure individuals understand their condition and are aware of how to hold those discussions with their doctors, so they feel empowered to assume a greater role in both diagnosis and treatment; that push/pull element of our approach is what propels demand, and it will keep being a priority for us now and always in this disease area?
Marc Frahm
analystOkay, thanks.
Mark Breidenbach
analystHey, good morning. I've just got a few brief questions. To begin with, how ought we to frame the pricing for PYRUKYND across Europe? Which treatments do you view as the closest analogues for this product there when it comes to price? Also, given the latest top line Phase 3 results for luspatercept in low and intermediate risk MDS, does that change or shape your strategy for advancing AG-946 in MDS at all? Perhaps you could also use this moment to point out the key ways 946 differs from luspatercept? Thanks.
Brian Goff
executiveSure. Morning, Mark. This is Brian. I'll handle the first question, then Sarah can definitely weigh in on MDS and what we're thinking. Regarding ex U.S., I won't go into detail on pricing right now. What I want to stress is that as we await and anticipate final approval for PYRUKYND in Europe and Great Britain, as mentioned during the call, that will represent a significant victory for PKD patients. In the near term, our choice has been to concentrate on securing access for PKD patients who we know are eager to obtain PYRUKYND. So, as Sarah said during the call, we take great pride in having a global managed access program set up; clearly that isn't commercial, simply to ensure adult PKD patients are able to get it; so pulling back, though, which I believe sits behind your question regarding the revenue opportunity, most of that we anticipate coming from the U.S. When we consider ex U.S., Europe in particular, we keep evaluating the commercial access plans, yet we're doing so alongside a broader view, namely the path we might see toward potentially bigger follow-on launches, chiefly thalassemia and sickle cell disease. I'll just note that at this point, when it comes to commercialization, we aren't aiming to establish our own sales force or commercial team ex-U.S., we're exploring partnering opportunities. Still, we'll be extremely selective about how we pursue that. All of this is what will steer us on how to commercialize and, to your question, what the right pricing should be.
Sarah Gheuens
executiveNow, regarding the second question about the luspatercept data — we don't think the recent results from that trial will affect our clinical development plans at all. Things are moving forward, and we remain quite enthusiastic about them. The key distinctions, I'd say, certainly include a completely different method of delivery. Ours is taken by mouth, which offers real convenience, particularly in an older patient group. More crucially, though, the way it works is entirely distinct, and we think activating PK to boost red blood cell function and survival matters greatly for this condition. Our clinical program has been built to include both ESA-naïve and ESA-refractory patients — essentially every patient with lower-risk MDS — and we see that as a strength of the way we've structured the program so far.
Mark Breidenbach
analystAll right. I really appreciate you having us on for questions, and congratulations on the quarter.
Brian Goff
executiveThank you as well.
Analyst
analystMorning. Jason here, filling in for Greg. We appreciate you fielding our questions, and congratulations on the headway. I was hoping you might give us a bit more detail regarding the early launch trends for PYRUKYND. Does the early demand line up with what you expected? Is broader awareness beginning to convert into additional patient starts? I'm just attempting to consider where a turning point might appear over the somewhat longer horizon. And regarding the early inventory stocking, is there any worry this might affect treatment initiations during this quarter? Thank you.
Richa Poddar
executiveAbsolutely. I'll begin, Jason, then ask Cecilia to address the inventory piece. From the standpoint of early demand, the way to frame it is that we will stay intensely concentrated on generating demand, since that matters greatly during this stage of the disease. A few things worth noting regarding the disease itself: I'd say we feel heartened by what this quarter showed us in terms of growth in new prescription enrollment forms, since that serves as the key leading indicator of how the launch is progressing. It's also a narrative of breadth — breadth regarding which kinds of physicians are writing the drug, and breadth regarding which kinds of patients have received prescriptions. So in the second complete quarter following launch, we keep witnessing that pattern unfold. With that said, two elements must be handled correctly and will require patience. The first is diagnostic efficiency. A sort of triage occurs on the diagnostic side in which PKD becomes misplaced within that funnel. Our aim, now that treatment exists, is to elevate that sense of urgency among physicians so they test for and identify PKD sooner within the diagnostic funnel than happens currently; that's the first one. The second element involves the fact that, because the disease is rare and chronic, lacking centers of excellence and involving a scattered patient population, the patient must take a highly active part in their own diagnosis and treatment. So giving them the tools and educating them so they understand how to hold those conversations with healthcare providers becomes extremely important, and that forms part of a tactical shift we undertook as well; thus our emphasis on generating demand will persist. As we've said previously, this will be a gradual, steady launch. We do not expect some kind of sudden hockey-stick turning point. So it will be gradual and steady, yet it truly establishes the groundwork for building our commercial capabilities, as Brian mentioned during his opening remarks, for what lies ahead with thalassemia and sickle cell.
Cecilia Jones
executiveYeah. And when it comes to inventory, we did observe some stock that you'd typically see during the first 2 quarters, but looking ahead, we expect inventory to stay at low levels. Just to remind everyone, our distribution network is limited — it's 1 specialty pharmacy and 1 specialty distributor.
Analyst
analystExcellent. So you believe that stock level is enough for the additional patient starts that will come up over the coming 1 quarter or thereabouts?
Cecilia Jones
executiveCorrect.
Analyst
analystGreat. We really appreciate you answering our questions.
Andrew Berens
analystHello, and thank you. If I overlooked this, I apologize, since I was switching back and forth between two calls. Could you share any insight regarding which genotypes the patients taking the drug have, and perhaps also those who aren't taking it? Although it's still early, we'd welcome any remarks about the persistence rate. Then, on the MDS opportunity, a substantial number of patients receive EPO off label, so how should we view a PKR drug coming into that treatment paradigm?
Richa Poddar
executiveHello, Andy, and thanks for asking. Regarding patient characteristics, prescriptions for the drug have covered a broad spectrum of patient types. Patients have received the drug regardless of age, splenectomy status and symptomology, whether regularly transfused or not regularly transfused. On your particular question about genotypes, no specifics have been given by us, but the way to think about it involves EPO or pyruvate criteria. Should the payer policy exclude patients with double non-missense mutations, those individuals couldn't obtain therapy unless they satisfied financial eligibility criteria and were able to join our free drug program; that's the single caveat, I'd note, depending on the payer policy. Broadly, though, physicians aren't observed by us restricting the drug's use according to a particular disease or patient characteristic.
Brian Goff
executiveAlso, Andy, let me mention something about persistency: at this moment, we're in the stage where the first data is beginning to come in. My take is that things are matching our expectations, yet it's still too soon to draw many conclusions, given where we sit this early in the launch. You might remember that in the clinical trial, the response rate with PYRUKYND came in at roughly 40% to 45%, and as we move into the real-world setting, the things we'll be watching are how payers react when treatment reaches the six-month point against the criteria they established, plus whether patient visits with their physician line up properly for the needed monitoring right at six months; we'll simply need to track that as time goes on, though we're feeling good about our progress on this front up to now. And MDS is something Sarah can address.
Sarah Gheuens
executiveYeah, absolutely. Regarding EPO and using it off-label — the way our program has been set up at present is focused on examining patients who might not have had any erythropoiesis-stimulating agent before, or those who haven't responded to treatment. At this moment, our proof-of-concept study does not have plans to include people currently taking EPO, since what we're really after right now is efficacy, and specifically efficacy for our own drug.
Andrew Berens
analystAll right. Appreciate it.
Andrea Tan
analystHello, everyone. Andrea here, filling in for Salveen. Thank you for allowing us to ask. Regarding the first item, we realize it's still early, yet perhaps one more inquiry about how PYRUKYND is priced. What's your approach for indications like thalassemia and sickle cell? Should we anticipate that matching the pricing you set for PKD?
Brian Goff
executiveYes. Andrea, I appreciate that. I'll handle it. Once more, on the topic of pricing, we won't provide details right now, though I'll simply note that from a directional standpoint, naturally the data is what lies ahead, and that data matters enormously. We're quite enthusiastic about how enrollment is advancing for thalassemia with ENERGIZE, the ENERGIZE-T trials, and also the Phase 2 portion in sickle cell disease through RISE UP. Our ambitions have been stated plainly: reaching that data point once enrollment succeeds. After we get it, we'll give pricing a careful review; broadly speaking, thalassemia represents a higher patient prevalence compared with where PKD stands. Then sickle cell, as you're aware, is a further increase beyond even thalassemia; we're discussing — for thalassemia, 18,000 to 23,000 patients across the U.S. and EU five < >. For sickle cell disease, within the U.S. by itself, we're around 100,000 patients. So that, together with the data, will steer us toward the right pricing choice. I realize this answer lacks specificity, but that's how I think you ought to view it at this point.
Andrea Tan
analystSure, no problem. Thank you very much; and perhaps a wider-ranging question — I was curious whether you might share some fresh perspective on the way you're considering possible business development moves going forward, and how those would fit together with the pipeline you already have? Thanks a lot.
Brian Goff
executiveAbsolutely; and I'll fold into that at least a nod to something we mentioned in our remarks earlier — we're genuinely delighted to have closed the TIBSOVO royalty monetization transaction with Sagard. What that accomplishes is clearly a further strengthening of our balance sheet, which, as we put it, already sits in an enviable spot, especially given this market; so it will increase our optionality regarding how we deploy capital. On BD, we hold an ambition to keep bolstering our pipeline while also diversifying, in particular diversifying away from PKR activation. And within the company, since we see BD as so vital to us over the long term, we've likewise grown the size of our internal BD team, and that ought to deliver more quality, more quantity, and more capacity when it comes to search, evaluation, and diligence. The way I frame it is that our sweet spot for business development would potentially be synergy with the rare, non-malignant hematology disease areas where our current focus lies; that could be one piece and/or leverage of the building rare disease capabilities we're developing, built on the foundation of our PKD launch, as Richa has discussed. And then finally, of course, for us in rare diseases, whatever we pursue, we'll need line of sight to transformational benefit for patients. From our standpoint, that's mission critical. So we aren't time-bounding when a deal gets done or how many deals we complete, but we do feel really good about our capital position, and our focus will be on value creation in a very disciplined approach.
Andrea Tan
analystAll right. I really appreciate the additional detail.
Danielle Brill
analystHey everyone. Morning, and thanks for fielding my question. What I'd like to understand is, among the patients who received a diagnosis through your Anemia ID kits, what share actually chooses to begin treatment? Thank you.
Richa Poddar
executiveHello, Danielle. Richa here. Thanks once more for raising that. As we've said previously, Anemia ID was built for hemolytic anemia where the cause is unknown. It isn't tailored to diagnosing PKD specifically. That means there's genuinely no compliant method for us to determine which patients identified via Anemia ID have started therapy. Our thinking on this is that we stay concentrated on generating demand, which covers the top-down effort — making sure healthcare providers properly prioritize PKD during diagnostic triage — alongside empowering and activating patients, so they understand they should hold those conversations with their healthcare providers, ensuring they get diagnosed and treated. That remains where our attention lies, though details about how Anemia ID translates into patient numbers simply aren't available.
Danielle Brill
analystGot it. So, do the physicians who place orders for the ID kits match the ones writing prescriptions for the drug?
Brian Goff
executiveAbsolutely, that can happen, yes. And just like we've mentioned before, in our view Anemia ID stands out among a small number of key instruments that matter greatly for keeping our launch moving forward. With Anemia ID, we feel we have exactly that. That said, I wouldn't frame it as something only available to those who write prescriptions.
Danielle Brill
analystUnderstood. Thank you for the question.
Brian Goff
executiveSure.
Brian Goff
executiveOkay. Many thanks, Justin, and I appreciate all of you for your questions and for staying engaged with what we're accomplishing. As ever, I'd like to express gratitude to my Agios teammates for their commitment and their drive to improve patients' lives. I'm also grateful to every patient, caregiver, and physician who works alongside us — collaborates with us, really, in countless ways — and particularly those enrolled in our clinical trials spanning multiple indications. The relationships we've built among stakeholders, combined with our shared work, drive the innovation impact we continue to deliver for individuals living with genetically defined diseases. So, I appreciate your time with us today, and you're welcome to disconnect at this point.
Operator
operatorThis concludes today’s conference call. Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.